Please use this identifier to cite or link to this item: https://hdl.handle.net/1/455
Title: Glycopyrronium once-daily significantly improves lung function and health status when combined with Salmeterol/Fluticasone in patients with COPD: The GLISTEN Study: A randomised controlled trial
Authors: Frith, Peter A ;Thompson, Philip ;Ratnavadivel, Rajeev ;Chang, Catherina ;Bremner, Peter ;Day, Peter ;Frenzel, Christina ;Nicol, Kurstjens 
Issue Date: Apr-2015
Source: Volume 70, Issue 6, pp. 519-527
Journal title: Thorax
Abstract: Background The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA). Methods This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50 µg, once-daily tiotropium (TIO) 18 µg or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily. The primary objective was to determine the non-inferiority of GLY+SAL/FP versus TIO+SAL/FP on trough FEV1 after 12 weeks. An important secondary objective was whether addition of GLY to SAL/FP was better than SAL/FP alone. Results 773 patients (mean FEV1 57.2% predicted) were randomised; 84.9% completed the trial. At week 12, GLY+SAL/FP demonstrated non-inferiority to TIO+SAL/FP for trough FEV1: least square mean treatment difference (LSMdiff) −7 mL (SE 17.4) with a lower limit for non-inferiority of −60 mL. There was significant increase in week 12 trough FEV1 with GLY+SAL/FP versus PLA+SAL/FP (LSMdiff 101 mL, p<0.001). At 12 weeks, GLY+SAL/FP produced significant improvement in St George's Respiratory Questionnaire total score versus PLA+SAL/FP (LSMdiff −2.154, p=0.02). GLY+SAL/FP demonstrated significant rescue medication reduction versus PLA+SAL/FP (LSMdiff −0.72 puffs/day, p<0.001). Serious adverse events were similar for GLY+SAL/FP, TIO+SAL/FP and PLA+SAL/FP with an incidence of 5.8%, 8.5% and 5.8%, respectively. Conclusions GLY+SAL/FP showed comparable improvements in lung function, health status and rescue medication to TIO+SAL/FP. Importantly, addition of GLY to SAL/FP demonstrated significant improvements in lung function, health status and rescue medication compared to SAL/FP. Trial registration number NCT01513460.
Description: Open Access: http://thorax.bmj.com/content/70/6/519.short
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/455
DOI: 10.1136/thoraxjnl-2014-206670
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/25841237
ISSN: 1468-3296
Publicaton type: Journal Article
Keywords: Respiratory
Drug Therapy
Study or Trial: Randomized Controlled Clinical Trial/Controlled Clinical Trial
Appears in Collections:Respiratory

Show full item record

Page view(s)

36
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.